U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. DDT COA #000057: Sickle Cell Pain Diary
  1. Drugs

DDT COA #000057: Sickle Cell Pain Diary

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN)
Division of Nonmalignant Hematology (DNH)

DDT COA Number
DDT COA #000057

Instrument Name
Sickle Cell Pain Diary

Disease/Condition
Sickle Cell Disease (SCD)
Concept of Interest
Pain intensity and pain interference

Context of Use
Pediatric patients with SCD

COA Type
PRO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
Lakshmanan Krishnamurti

Contact(s)
Lakshmanan Krishnamurti

Date Accepted into CDER’s COA Qualification Program
February 14, 2014

Submission and Regulatory Correspondence History

Qualification Submission

Date

FDA Submission Decision & Recommendations

Date

--

--

Transition Letter to 507 Process

9/5/19

Back to Top